# OnCo record her2-ihc-0 (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/her2-ihc-0/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "her2-ihc-0" ;
  schema:name "HER2 IHC 0 (HER2-negative, including ultralow)"@en ;
  schema:alternateName "HER2 IHC 0"@en, "HER2 0"@en, "IHC 0"@en, "HER2-negative IHC"@en, "HER2 null"@en, "IHC 0 with membrane staining"@en ;
  schema:description "IHC 0 is no HER2 staining, or faint staining in 10 percent or fewer cells. It is HER2-negative, but the label now separates true zero from 'IHC 0 with membrane staining', the ultralow group that trastuzumab deruxtecan can treat in hormone-receptor-positive breast cancer."@en ;
  schema:url <https://onco.cc/biomarkers/her2-ihc-0/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6>, <https://doi.org/10.1200/JCO.2018.77.8738> ;
  onco:tag "biomarker", "her2" ;
  onco:related <https://onco.cc/biomarkers/her2-ultralow/>, <https://onco.cc/biomarkers/her2-ihc-1-plus/>, <https://onco.cc/biomarkers/her2-low-ihc/> ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/her2-testing-assays/> ;
  onco:terms <https://onco.cc/terms/her2-low/>, <https://onco.cc/terms/ihc/> .